Suptavumab
From Wikipedia, the free encyclopedia
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Human |
| Target | respiratory syncytial virus fusion protein |
| Clinical data | |
| Other names | REGN2222 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6502H10038N1726O2020S42 |
| Molar mass | 146054.41 g·mol−1 |
Suptavumab (INN;[1] development code (REGN2222) is a humanized monoclonal antibody designed for the prevention of medically attended lower respiratory tract disease due to respiratory syncytial virus.[2]
This experimental drug candidate was being developed by Regeneron Pharmaceuticals Inc until it was discontinued after unsuccessful Phase III clinical trials.[3][4]
